Understand the source comparison
Peptides for Prostate Health Protocol Evidence Guide: Comparison Table
Before selecting a peptide for research or therapeutic exploration, understanding the evidence quality, mechanism specificity, and practical administration requirements is essential. This comparison evaluates the three most-studied peptides for prostate-relate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for research or therapeutic exploration, understanding the evidence quality, mechanism specificity, and practical administration requirements is essential. This comparison evaluates the three most-studied peptides for prostate-related applications.
- BPC-157
- Angiogenesis, VEGF upregulation, NO pathway modulation, fibroblast activation
- Rodent prostatitis models show reduced inflammatory cell infiltration and prostatic edema; no human trials
- 250–500 mcg daily subcutaneous
- Subcutaneous injection
- Strong mechanistic rationale for tissue repair; zero human prostate-specific data limits clinical extrapolation
- Thymosin Beta-4
- Actin regulation, TGF-β inhibition, immune cell modulation, anti-fibrotic signaling
- Indirect evidence from fibrosis models (lung, cardiac); mechanistically relevant to prostatic fibrosis but no prostate-specific trials
- 2–5 mg twice weekly subcutaneous
- Best-supported safety profile from cardiac trials; prostate application is mechanistic inference only
- Epithalon
- Telomerase activation, pineal gland modulation, melatonin synthesis
- Observational longevity research; rodent models show reduced age-related prostatic hyperplasia; circadian-prostate links are epidemiological
- 5–10 mg in 10-day cycles
- Weakest direct prostate evidence; strongest as adjunct to circadian optimization rather than standalone prostate therapy